Lars Holten-Andersen, Susanne Pihl, Caroline E Rasmussen, Joachim Zettler, Guillaume Maitro, Julia Baron, Stefan Heinig, Eric Hoffmann, Thomas Wegge, Mathias Krusch, Frank Faltinger, Steffen Killian, Kennett Sprogoe, David B Karpf, Vibeke Miller Breinholt, Felix Cleemann
Hypoparathyroidism (HP) is a condition of PTH deficiency leading to abnormal calcium and phosphate metabolism. The mainstay of therapy consists of vitamin D and calcium supplements, as well as adjunct Natpara [PTH(1-84)]. However, neither therapy optimally controls urinary calcium (uCa) or significantly reduces the incidence of hypercalcemia and hypocalcemia. TransCon PTH, a sustained-release prodrug of PTH(1-34) in development for the treatment of HP, was designed to overcome these limitations. To determine the pharmacokinetics and pharmacodynamics of TransCon PTH, single and repeat s...
July 10, 2019: Journal of Bone and Mineral Research